Controlled-diffusion centrifugal microfluidic for rapid antibiotic susceptibility testing

Zheng Pang1, Shunji Li1, Shangang Wang1

  • 1The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.

Analytica Chimica Acta
|January 5, 2024
PubMed

Insights

A novel centrifugal microfluidic platform offers rapid antimicrobial susceptibility testing (AST) within hours. This technology provides a low-cost, portable solution for determining minimum inhibitory concentration (MIC) values, combating antimicrobial resistance (AMR).

Area of Science:

  • Biomedical Engineering
  • Microfluidics
  • Antimicrobial Resistance Research

Background:

  • Antibiotic abuse fuels antimicrobial resistance (AMR), a global public safety concern.
  • Traditional antimicrobial susceptibility testing (AST) methods are slow, labor-intensive, and expensive.
  • Rapid AST is essential for effective treatment and AMR containment.

Purpose of the Study:

  • To develop a rapid, precise, and cost-effective platform for antimicrobial susceptibility testing (AST).
  • To establish a controlled-diffusion centrifugal microfluidic (CCM) platform for determining minimum inhibitory concentration (MIC) values.
  • To create an integrated mobile detection system for point-of-care AST.

Main Methods:

  • A controlled-diffusion centrifugal microfluidic (CCM) platform was designed to generate antibiotic concentration gradients.
  • Antibiotic and buffer solutions were diffused along a microchannel within 3 minutes.
  • Bacterial suspension and solutions were combined in reaction chambers via centrifugation for rapid MIC determination.

Main Results:

  • The CCM platform successfully determined minimum inhibitory concentration (MIC) values for three common antibiotics within 4-9 hours.
  • The method demonstrated high precision in MIC value acquisition.
  • An integrated mobile detection platform was developed for automated MIC acquisition, enhancing practicality and reducing costs.

Conclusions:

  • The proposed CCM platform offers a simple, low-cost, and portable solution for rapid AST.
  • This technology has broad clinical and in vitro applications for combating antimicrobial resistance.
  • The CCM platform facilitates faster clinical decisions and supports point-of-care testing needs.

Related Concept Videos